Clinical Trials

Accrual Status
Limit to SWOG Trials

1045 Results

    View
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2419

    Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
    Status Notes
    Active as of 4/22/2026.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    04-22-2026
    ClinicalTrials.gov Registry Number
    NCT07383441
    Open
    Phase
    Accrual
    6%
    SWOG Clinical Trial Number
    SN2426

    A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Sarcoma
    Activated
    01-28-2026
    ClinicalTrials.gov Registry Number
    07042295
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2433

    Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-26-2025
    ClinicalTrials.gov Registry Number
    NCT06998940
    Open
    Phase
    Accrual
    6%
    SWOG Clinical Trial Number
    21CTP.HN01

    Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis
    Status Notes
    Activation - Effective 09/15/2025

    SWOG Clinical Trials Partinerships
    https://www.swogctp.org/trials/21ctphn01/
    Research Committee(s)
    SWOG CTP
    Head and Neck Cancer
    Activated
    09-15-2025
    ClinicalTrials.gov Registry Number
    07062354
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2409

    PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Status Notes
    This study is open to accrual, effective 9/8/2025 at 12:00 p.m. PT.
    Research Committee(s)
    Lung Cancer
    Activated
    09-08-2025
    Open
    Phase
    Accrual
    11%
    SWOG Clinical Trial Number
    S2427

    Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
    Status Notes
    Active as of 9/4/2025.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    09-04-2025
    ClinicalTrials.gov Registry Number
    07061964